BeyondSpring Inc. BYSI shares are trading higher after the company announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel for non-small cell lung cancer, which showed the study met its primary endpoint and key secondary endpoints.
Plinabulin, BeyondSpring’s lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen-presenting cell (APC) inducer.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies.
BeyondSpring's stock was trading about 140% higher at $23.07 per share on Wednesday at the time of publication. The stock has a 52-week high of $28.74 and a 52-week low of $8.90.
See also: Best Growth Stocks Right Now
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
